Felipe Duran has bought IBIO on 2 days since Jan 2025
CFO at iBio, Inc.
SEC CIK 0001964267 · Filings on SEC.gov ↗
Felipe Duran's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
2 filings since Jan 2025, newest first
About Felipe Duran
Felipe Duran is the Chief Financial Officer (CFO) of iBio, Inc. (NYSE: IBIO), a biotechnology company focused on AI-driven precision antibody immunotherapies and cardiometabolic obesity therapeutics.( Appointed permanently to the role on June 27, 2023, after serving as interim CFO since early 2023, Duran previously held the position of Vice President of Financial Planning and Analysis at iBio from April 2021, where he led financial restructuring, negotiations, and oversight of key acquisitions.(
Duran brings extensive experience in pharmaceutical finance, having served as Executive Director (CFO) of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, where he implemented pricing strategies that boosted regional net sales by double digits, turned around a subsidiary to EBITDA positivity, and managed U.S. R&D finance.( Earlier roles include strategic planning positions at Teva Pharmaceuticals in growth markets and Latin America, and Manager of FP&A at Noven Pharmaceuticals and Bupa.( He holds a B.A. in Finance and an M.B.A. from the University of Miami.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.